The Biden administration wants to expand coverage of anti-obesity medications to millions on Medicare, Medicaid ...

Now that millions of people have used the drugs, several obesity experts told The Associated Press that perhaps 20% of ...

Compared with standard AUD medications, the use of semaglutide and liraglutide was linked to a lower risk for alcohol use ...

The glucose-lowering and weight-reducing drug class appears to benefit the heart and kidneys in people with lupus and lupus nephritis, independently of glucose-lowering and weight loss.

The combined reduction in the risk of kidney failure, worsening kidney function and death due to kidney disease was 19, researchers found.

The biggest and most comprehensive analysis of glucagon-like peptide-1 (GLP-1) receptor agonists on kidney and cardiovascular ...

Lexaria Bioscience (LEXX) announced that dosing has been completed for human pilot study #3 investigating a DehydraTECH-processed version of ...

Obesity experts have said that nearly 20% patients may not respond well to GLP-1 medications. They explained that these drugs do not work on one-size-fits-all principle.

In the US, liraglutide, semaglutide, and tirzepatide are currently under investigation for their ability to stimulate weight ...

Researchers compared rates of gout medication initiation among patients with gout and type 2 diabetes receiving SGLT2 inhibitors or GLP-1 receptor agonists.